STAT3 and ovarian carcinoma: At the clinical level, there is increasing evidence that activation of the STAT3 pathway significantly correlates with reduced survival of rare ovarian cancers, thereby highlighting the importance of STAT3 as a prospective therapeutic target for cancer treatment.15